Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges
Frontiers in Oncology · 16.07.2026 · 16
DOI: 10.3389/fonc.2026.1860901 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 16.07.2026. Verfasst von Xiaomei Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Capital Medical University Electric Power Teaching Hospital, Beijing, China. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gynecologic malignancies, including cervical, endometrial, and ovarian cancers, remain major threats to women’s health [1]. Despite advances in conventional treatments, outcomes for advanced or recurrent disease remain unsatisfactory [2]. Immune checkpoint inhibitors (ICIs) offer new hope but are limited by low response rates as monotherapy [3]. This review summarizes the application of ICIs in gynecologic cancers, focusing on combination strategies with chemotherapy, radiotherapy, PARP inhibitors, and anti-angiogenic agents, along with their mechanisms and clinical progress [4]. Key clinical trial data are presented to demonstrate the efficacy of combination approaches. Current challenges are also analyzed, including drug resistance, adverse events, treatment optimization, and biomarker development [5]. ICI-based combination therapy has revolutionized the management of advanced gynecologic cancers. The key issue now is how to optimize these regimens in clinical practice, which requires deeper understanding of the tumor immune microenvironment, reliable multi-dimensional biomarkers, and well-designed clinical trials [6].
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Capital Medical University Electric Power Teaching Hospital, Beijing, China.
- Department of Obstetrics and Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Hu, X., Zhou, M., & Kong, W. (2026). Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1860901
Vancouver
Hu X, Zhou M, Kong W. Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1860901
BibTeX
@article{Hu2026,
author = {Hu, Xiaomei and Zhou, Mingshu and Kong, Weimin},
title = {Combined therapy strategies of immune checkpoint inhibitors in gynecologic oncology: progress and challenges},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1860901}
}
EUVIMED